MASLD/MASH (NAFLD/NASH) - New Nomenclature, Risk Stratification, and Therapeutics on the Horizon

This past installment of the Division of Occupational and Environmental Medicine grand rounds, on Friday 20-December-2024, focused on MASLD/MASH (NAFLD/NASH) as described by Meena B. Bansal, MD.
Dr. Meena Bansal joined the faculty at Mount Sinai in 2001. She received her medical degree and trained in Internal Medicine at Cornell University and completed her Gastroenterology fellowship at the University of Pennsylvania. In 2002 she became the Transplant Hepatology Fellowship Director, in 2013 Director of Translational Research in the Division of Liver Diseases, and in 2015 Chief Medical Officer of Mount Sinai Care LLC and Deputy Chief Medical Officer for Mount Sinai Health Partners. While remaining clinically active, she has also developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis/cirrhosis in an effort to develop novel anti-fibrotic therapies. Her current research interests focus on how HIV may promote hepatic inflammation and fibrosis as well as novel treatments for metabolic dysfunction-associated steatohepatitis (MASH). She is the principal investigator in a number of clinical trials for the treatment of Hepatitis C and MASH.